Use of mycophenolate mofetil in inflammatory bowel disease

Table 1 Demographics of the IBD patients using the Montreal classification

	CD patients n = 9	UC/IBDU patients n = 5
Gender: male	57.1% (8/14)	57.1% (8/14)
Age at diagnosis
Mean ± SE (range)	38.6 ± 13.3 yr (19-54)	44.0 ± 12.7 yr (30-63)
A1- ≤ 16	0% (0/9)	0% (0/5)
A2-17-40	44.4% (4/9)	40% (2/5)
A3- > 40	55.6% (5/9)	60% (3/5)
Disease duration
Mean (range)	10.4 yr (1-26)	9.8 yr (1-28)
Crohn’s disease
L1-terminal ileum	22.2% (2/9)
L2-colon	33.3% (3/9)
L3-ileocolonic	44.4% (4/9)
L4-upper GI	11.1% (1/9)
P-perianal	22.2% (2/9)
B1-inflammatory	44.4% (4/9)
B2-stricturing	33.3% (3/9)
B3-perforating	22.2% (2/9)
Ulcerative colitis/IBDU
E1-proctitis		20% (1/5)
E2-left sided		40% (2/5)
E3-extensive		40% (2/5)
Raised CRP	55.6% (5/9)	80.0% (4/5)